Extensively Hydrolyzed Formula and Infant Colic Symptoms: Secondary Analysis of a Prospective Cohort Study.

IF 1 4区医学 Q3 PEDIATRICS

Clinical Pediatrics Pub Date : 2024-11-01 Epub Date: 2024-03-10 DOI:10.1177/00099228241236033

Jerry Mack Brown, Jessica Victoria Baran, Luke Lamos, Jesse Beacker, Jared Florio, Lea Victoria Oliveros, Abigail Lea Fabbrini, Andrew Arthur Farrar, Jon Arvid Vanderhoof, Michael John Wilsey

{"title":"Extensively Hydrolyzed Formula and Infant Colic Symptoms: Secondary Analysis of a Prospective Cohort Study.","authors":"Jerry Mack Brown, Jessica Victoria Baran, Luke Lamos, Jesse Beacker, Jared Florio, Lea Victoria Oliveros, Abigail Lea Fabbrini, Andrew Arthur Farrar, Jon Arvid Vanderhoof, Michael John Wilsey","doi":"10.1177/00099228241236033","DOIUrl":null,"url":null,"abstract":"<p><p>Cow's milk protein allergy (CMPA) affects 2% to 3% of infants and is managed with hypoallergenic formulas. The 2022 recalls of infant formulas due to factors including contamination led to specialty formula shortages, highlighting CMPA management challenges. Understanding health care providers' (HCPs) decision-making in transitioning to alternative formulas during shortages is crucial. Limited attention has been given to how pediatric physicians make these choices. This study utilized US HCPs' de-identified survey data to assess driving factors when switching extensively hydrolyzed formulas during shortages. A total of 104 eligible HCPs participated, including general pediatrics, pediatric allergy/immunology, and pediatric gastroenterology specialists. Safety, tolerability, and efficacy were identified as top factors for switching formulas. Formula 1 was considered well-tolerated, patient-accepted, and safe by all HCPs. Most expressed strong belief in Formula 1's safety and effectiveness. Findings inform CMPA management during shortages, offering guidance to HCPs for suitable formula selection and enhanced infant care.</p>","PeriodicalId":10363,"journal":{"name":"Clinical Pediatrics","volume":" ","pages":"1579-1584"},"PeriodicalIF":1.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00099228241236033","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Cow's milk protein allergy (CMPA) affects 2% to 3% of infants and is managed with hypoallergenic formulas. The 2022 recalls of infant formulas due to factors including contamination led to specialty formula shortages, highlighting CMPA management challenges. Understanding health care providers' (HCPs) decision-making in transitioning to alternative formulas during shortages is crucial. Limited attention has been given to how pediatric physicians make these choices. This study utilized US HCPs' de-identified survey data to assess driving factors when switching extensively hydrolyzed formulas during shortages. A total of 104 eligible HCPs participated, including general pediatrics, pediatric allergy/immunology, and pediatric gastroenterology specialists. Safety, tolerability, and efficacy were identified as top factors for switching formulas. Formula 1 was considered well-tolerated, patient-accepted, and safe by all HCPs. Most expressed strong belief in Formula 1's safety and effectiveness. Findings inform CMPA management during shortages, offering guidance to HCPs for suitable formula selection and enhanced infant care.

查看原文本刊更多论文

广泛水解配方奶粉与婴儿腹绞痛症状：一项前瞻性队列研究的二次分析。

2%-3%的婴儿会对牛奶蛋白过敏（CMPA），可通过低敏配方奶粉进行控制。2022 年，由于污染等因素，婴儿配方奶粉被召回，导致特殊配方奶粉短缺，凸显了 CMPA 管理方面的挑战。了解医疗保健提供者（HCP）在短缺期间过渡到替代配方奶粉的决策至关重要。人们对儿科医生如何做出这些选择的关注有限。本研究利用美国医护人员的去标识化调查数据来评估在奶粉短缺期间改用广泛水解配方奶粉的驱动因素。共有 104 名符合条件的 HCP 参与了调查，其中包括普通儿科、儿科过敏/免疫科和儿科胃肠病学专家。安全性、耐受性和有效性被认为是更换配方奶粉的首要因素。所有 HCP 都认为配方 1 具有良好的耐受性、患者接受度和安全性。大多数人表示坚信配方 1 的安全性和有效性。研究结果为配方奶粉短缺期间的 CMPA 管理提供了参考，为保健医生选择合适的配方奶粉和加强婴儿护理提供了指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Pediatrics 医学-小儿科

CiteScore

2.10

自引率

6.20%

发文量

189

审稿时长

3-8 weeks

期刊介绍： Clinical Pediatrics (CLP) a peer-reviewed monthly journal, is a must read for the busy pediatrician. CLP contains state-of-the-art, accurate, concise and down-to earth information on practical, everyday child care topics whether they are clinical, scientific, behavioral, educational, or ethical.